Walt Disney Co vs Twist Bioscience Corp — how do they compare? Walt Disney Co trades at $103.22 (market cap $178.76B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Walt Disney Co is far larger — about 23.2× Twist Bioscience Corp's market cap, and Walt Disney Co pays a 1.45% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DIS | TWST | |
|---|---|---|
Market Cap | $178.76B | $7.72B |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $124.88 |
52-Week Low | $92.40 | $24.16 |
Enterprise Value | $219.62B | $7.65B |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.20, down 1.62% on the day, amid a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.06 exceeding estimates by $0.20. Revenue growth has been steady, reaching $94.43 billion in 2025, while net income surged to $12.40 billion. Analyst sentiment remains positive with a consensus price target of $126.00, representing a 22% upside. Recent news highlights advertising opportunities with major events like the Super Bowl and ongoing FCC regulatory challenges.
The outlook for Disney is favorable, driven by earnings momentum, strategic investments in parks and streaming, and a dominant position in entertainment. Key risks include regulatory disputes with the FCC, box office underperformance of recent films, and economic sensitivity. With a P/E of 21.35 and robust cash flow, the stock offers value for long-term investors despite near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →